This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): zanamivir for inhalation
Description: The active component of Relenza is zanamivir. The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.
GlaxoSmithKline no longer reports revenues for Relenza as of Q1 2012.
Relenza was invented in Australia in the 1980s and licensed to Glaxo Wellcome by Biota Holdings Limited in 1989. This license gave to GlaxoWellcome the rights to develop Relenza and to market the product worldwide in return for royalty payments. This royalty is 7% of net sales (except in Australia, New Zealand, Indonesia and South Africa, where it is 10%).
In September 2006, GlaxoSmithKline announced it signed a licensing agreement granting Simcere the right to manufacture and sell zanamivir in China, Indonesia, Thailand, Vietnam and all Least Developed Countries (LDCs). Under the sub-license, Biota will be entitled to receive royalties on sales by Simcere.
In April 2012, Nabi Biopharmaceuticals announced plans to merge with Biota Holdings. The execution of the merger implementation agreement will form a combined company to be named Biota Pharmaceuticals. The merger completed in November 2012.
Partners: Aviragen Therapeutics, Inc. Simcere Pharmaceutical Group
Pink Sheet Relenza Clinical Protocols
Pink Sheet Relenza FDA Reviewers
Pink Sheet Relenza Clinical Development
Additional information available to subscribers only: